ID   AHR_HUMAN               Reviewed;         848 AA.
AC   P35869; A4D130; Q13728; Q13803; Q13804;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   28-JUN-2023, entry version 224.
DE   RecName: Full=Aryl hydrocarbon receptor {ECO:0000303|PubMed:8393992};
DE            Short=Ah receptor {ECO:0000303|PubMed:8393992};
DE            Short=AhR {ECO:0000303|PubMed:8393992};
DE   AltName: Full=Class E basic helix-loop-helix protein 76;
DE            Short=bHLHe76;
DE   Flags: Precursor;
GN   Name=AHR {ECO:0000303|PubMed:8393992, ECO:0000312|HGNC:HGNC:348};
GN   Synonyms=BHLHE76 {ECO:0000312|HGNC:HGNC:348};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=8393992; DOI=10.1093/nar/21.15.3578;
RA   Itoh S., Kamataki T.;
RT   "Human Ah receptor cDNA: analysis for highly conserved sequences.";
RL   Nucleic Acids Res. 21:3578-3578(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=8246913;
RA   Dolwick K.M., Schmidt J.V., Carver L.A., Swanson H.I., Bradfield C.A.;
RT   "Cloning and expression of a human Ah receptor cDNA.";
RL   Mol. Pharmacol. 44:911-917(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7883760; DOI=10.1093/oxfordjournals.jbchem.a124605;
RA   Ema M., Matsushita N., Sogawa K., Ariyama T., Inazawa J., Nemoto T.,
RA   Ota M., Oshimura M., Fujii-Kuriyama Y.;
RT   "Human arylhydrocarbon receptor: functional expression and chromosomal
RT   assignment to 7p21.";
RL   J. Biochem. 116:845-851(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 5-235; 388-461 AND 764-848.
RX   PubMed=16696038; DOI=10.1136/mp.49.1.m12;
RA   Bennett P., Ramsden D.B., Williams A.C.;
RT   "Complete structural characterisation of the human aryl hydrocarbon
RT   receptor gene.";
RL   Clin. Mol. Pathol. 49:M12-M16(1996).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 236-341, AND TISSUE SPECIFICITY.
RX   PubMed=7515333; DOI=10.1093/carcin/15.5.801;
RA   Hayashi S., Watanabe J., Nakachi K., Eguchi H., Gotoh O., Kawajiri K.;
RT   "Interindividual difference in expression of human Ah receptor and related
RT   P450 genes.";
RL   Carcinogenesis 15:801-806(1994).
RN   [10]
RP   FUNCTION, AND MUTAGENESIS OF VAL-381.
RX   PubMed=7961644; DOI=10.1016/s0021-9258(18)46990-6;
RA   Ema M., Ohe N., Suzuki M., Mimura J., Sogawa K., Ikawa S.,
RA   Fujii-Kuriyama Y.;
RT   "Dioxin binding activities of polymorphic forms of mouse and human
RT   arylhydrocarbon receptors.";
RL   J. Biol. Chem. 269:27337-27343(1994).
RN   [11]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=10395741; DOI=10.1006/abbi.1999.1282;
RA   Nguyen T.A., Hoivik D., Lee J.-E., Safe S.;
RT   "Interactions of nuclear receptor coactivator/corepressor proteins with the
RT   aryl hydrocarbon receptor complex.";
RL   Arch. Biochem. Biophys. 367:250-257(1999).
RN   [12]
RP   INDUCTION.
RX   PubMed=11259615; DOI=10.1124/mol.59.4.716;
RA   Wolff S., Harper P.A., Wong J.M.Y., Mostert V., Wang Y., Abel J.;
RT   "Cell-specific regulation of human aryl hydrocarbon receptor expression by
RT   transforming growth factor-beta(1).";
RL   Mol. Pharmacol. 59:716-724(2001).
RN   [13]
RP   REVIEW ON ROLE IN CELL CYCLE.
RX   PubMed=12213388; DOI=10.1016/s0009-2797(02)00069-8;
RA   Puga A., Xia Y., Elferink C.;
RT   "Role of the aryl hydrocarbon receptor in cell cycle regulation.";
RL   Chem. Biol. Interact. 141:117-130(2002).
RN   [14]
RP   INTERACTION WITH NEDD8.
RX   PubMed=12215427; DOI=10.1074/jbc.m202413200;
RA   Antenos M., Casper R.F., Brown T.J.;
RT   "Interaction with Nedd8, a ubiquitin-like protein, enhances the
RT   transcriptional activity of the aryl hydrocarbon receptor.";
RL   J. Biol. Chem. 277:44028-44034(2002).
RN   [15]
RP   INTERACTION WITH IVNS1ABP.
RX   PubMed=16582008; DOI=10.1124/mol.106.024380;
RA   Dunham E.E., Stevens E.A., Glover E., Bradfield C.A.;
RT   "The aryl hydrocarbon receptor signaling pathway is modified through
RT   interactions with a Kelch protein.";
RL   Mol. Pharmacol. 70:8-15(2006).
RN   [16]
RP   REVIEW ON VARIANTS.
RX   PubMed=12213390; DOI=10.1016/s0009-2797(02)00071-6;
RA   Harper P.A., Wong J.M.Y., Lam M.S.M., Okey A.B.;
RT   "Polymorphisms in the human AH receptor.";
RL   Chem. Biol. Interact. 141:161-187(2002).
RN   [17]
RP   REVIEW ON LIGANDS.
RX   PubMed=18076143; DOI=10.1021/tx7001965;
RA   Nguyen L.P., Bradfield C.A.;
RT   "The search for endogenous activators of the aryl hydrocarbon receptor.";
RL   Chem. Res. Toxicol. 21:102-116(2008).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH TIPARP.
RX   PubMed=23275542; DOI=10.1093/nar/gks1337;
RA   MacPherson L., Tamblyn L., Rajendra S., Bralha F., McPherson J.P.,
RA   Matthews J.;
RT   "2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TiPARP,
RT   ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon
RT   receptor transactivation.";
RL   Nucleic Acids Res. 41:1604-1621(2013).
RN   [20]
RP   FUNCTION, AND ADP-RIBOSYLATION.
RX   PubMed=30373764; DOI=10.1042/bcj20180347;
RA   Gomez A., Bindesboell C., Somisetty V.S., Grimaldi G., Hutin D.,
RA   MacPherson L., Ahmed S., Tamblyn L., Cho T., Nebb H.I., Moen A.,
RA   Anonsen J.H., Grant D.M., Matthews J.;
RT   "Characterization of TCDD-Inducible Poly-ADP-Ribose Polymerase
RT   (TIPARP/ARTD14) Catalytic Activity.";
RL   Biochem. J. 475:3827-3846(2018).
RN   [21]
RP   TISSUE SPECIFICITY, AND INVOLVEMENT IN RP85.
RX   PubMed=29726989; DOI=10.1093/hmg/ddy165;
RA   Zhou Y., Li S., Huang L., Yang Y., Zhang L., Yang M., Liu W., Ramasamy K.,
RA   Jiang Z., Sundaresan P., Zhu X., Yang Z.;
RT   "A splicing mutation in aryl hydrocarbon receptor associated with retinitis
RT   pigmentosa.";
RL   Hum. Mol. Genet. 27:2563-2572(2018).
RN   [22]
RP   FUNCTION.
RX   PubMed=32818467; DOI=10.1016/j.cell.2020.07.038;
RA   Sadik A., Somarribas Patterson L.F., Oeztuerk S., Mohapatra S.R.,
RA   Panitz V., Secker P.F., Pfaender P., Loth S., Salem H., Prentzell M.T.,
RA   Berdel B., Iskar M., Faessler E., Reuter F., Kirst I., Kalter V.,
RA   Foerster K.I., Jaeger E., Guevara C.R., Sobeh M., Hielscher T., Poschet G.,
RA   Reinhardt A., Hassel J.C., Zapatka M., Hahn U., von Deimling A., Hopf C.,
RA   Schlichting R., Escher B.I., Burhenne J., Haefeli W.E., Ishaque N.,
RA   Boehme A., Schaeuble S., Thedieck K., Trump S., Seiffert M., Opitz C.A.;
RT   "IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes
RT   tumor progression.";
RL   Cell 182:1252-1270(2020).
RN   [23]
RP   FUNCTION.
RX   PubMed=32866000; DOI=10.1021/acs.jafc.0c03735;
RA   Zhang X., Gan M., Li J., Li H., Su M., Tan D., Wang S., Jia M., Zhang L.,
RA   Chen G.;
RT   "An endogenous indole pyruvate pathway for tryptophan metabolism mediated
RT   by IL4I1.";
RL   J. Agric. Food Chem. 68:10678-10684(2020).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH ARNT, AND MUTAGENESIS OF
RP   SER-36; HIS-39; ARG-40; LEU-50; ALA-79; PHE-82 AND 118-LEU--LEU-122.
RX   PubMed=34521881; DOI=10.1038/s41598-021-97507-w;
RA   Haidar R., Henkler F., Kugler J., Rosin A., Genkinger D., Laux P., Luch A.;
RT   "The role of DNA-binding and ARNT dimerization on the nucleo-cytoplasmic
RT   translocation of the aryl hydrocarbon receptor.";
RL   Sci. Rep. 11:18194-18194(2021).
RN   [25] {ECO:0007744|PDB:5NJ8}
RP   X-RAY CRYSTALLOGRAPHY (3.30 ANGSTROMS) OF 23-273 IN COMPLEXES WITH ARNT AND
RP   DNA, REGION, MUTAGENESIS OF ARG-40; LEU-50; VAL-74; ALA-79; PHE-82;
RP   LEU-118; LEU-122; PHE-136 AND ILE-154, FUNCTION, AND INTERACTION WITH ARNT.
RX   PubMed=28602820; DOI=10.1016/j.str.2017.05.008;
RA   Schulte K.W., Green E., Wilz A., Platten M., Daumke O.;
RT   "Structural Basis for Aryl Hydrocarbon Receptor-Mediated Gene Activation.";
RL   Structure 25:1025-1033(2017).
RN   [26]
RP   VARIANT LYS-554.
RX   PubMed=7550366; DOI=10.1097/00008571-199506000-00003;
RA   Kawajiri K., Watanabe J., Eguchi H., Nakachi K., Kiyohara C., Hayashi S.;
RT   "Polymorphisms of human Ah receptor gene are not involved in lung cancer.";
RL   Pharmacogenetics 5:151-158(1995).
RN   [27]
RP   VARIANTS LYS-554 AND ILE-570.
RX   PubMed=10739168; DOI=10.1097/00008571-200002000-00003;
RA   Smart J., Daly A.K.;
RT   "Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor
RT   and GSTM1 polymorphisms.";
RL   Pharmacogenetics 10:11-24(2000).
RN   [28]
RP   VARIANTS LYS-554 AND VAL-786.
RX   PubMed=11698344; DOI=10.1093/carcin/22.11.1819;
RA   Cauchi S., Stucker I., Solas C., Laurent-Puig P., Cenee S., Hemon D.,
RA   Jacquet M., Kremers P., Beaune P., Massaad-Massade L.;
RT   "Polymorphisms of human aryl hydrocarbon receptor (AhR) gene in a French
RT   population: relationship with CYP1A1 inducibility and lung cancer.";
RL   Carcinogenesis 22:1819-1824(2001).
RN   [29]
RP   VARIANTS SER-517 AND ILE-570.
RX   PubMed=11689007; DOI=10.1006/bbrc.2001.5861;
RA   Wong J.M.Y., Okey A.B., Harper P.A.;
RT   "Human aryl hydrocarbon receptor polymorphisms that result in loss of
RT   CYP1A1 induction.";
RL   Biochem. Biophys. Res. Commun. 288:990-996(2001).
CC   -!- FUNCTION: Ligand-activated transcription factor that enables cells to
CC       adapt to changing conditions by sensing compounds from the environment,
CC       diet, microbiome and cellular metabolism, and which plays important
CC       roles in development, immunity and cancer (PubMed:30373764,
CC       PubMed:23275542, PubMed:7961644, PubMed:32818467). Upon ligand binding,
CC       translocates into the nucleus, where it heterodimerizes with ARNT and
CC       induces transcription by binding to xenobiotic response elements (XRE)
CC       (PubMed:30373764, PubMed:23275542, PubMed:7961644). Regulates a variety
CC       of biological processes, including angiogenesis, hematopoiesis, drug
CC       and lipid metabolism, cell motility and immune modulation
CC       (PubMed:12213388). Xenobiotics can act as ligands: upon xenobiotic-
CC       binding, activates the expression of multiple phase I and II xenobiotic
CC       chemical metabolizing enzyme genes (such as the CYP1A1 gene)
CC       (PubMed:7961644). Mediates biochemical and toxic effects of halogenated
CC       aromatic hydrocarbons (PubMed:7961644, PubMed:34521881). Next to
CC       xenobiotics, natural ligands derived from plants, microbiota, and
CC       endogenous metabolism are potent AHR agonists (PubMed:18076143).
CC       Tryptophan (Trp) derivatives constitute an important class of
CC       endogenous AHR ligands (PubMed:32866000, PubMed:32818467). Acts as a
CC       negative regulator of anti-tumor immunity: indoles and kynurenic acid
CC       generated by Trp catabolism act as ligand and activate AHR, thereby
CC       promoting AHR-driven cancer cell motility and suppressing adaptive
CC       immunity (PubMed:32818467). Regulates the circadian clock by inhibiting
CC       the basal and circadian expression of the core circadian component PER1
CC       (PubMed:28602820). Inhibits PER1 by repressing the CLOCK-BMAL1
CC       heterodimer mediated transcriptional activation of PER1
CC       (PubMed:28602820). The heterodimer ARNT:AHR binds to core DNA sequence
CC       5'-TGCGTG-3' within the dioxin response element (DRE) of target gene
CC       promoters and activates their transcription (PubMed:28602820).
CC       {ECO:0000269|PubMed:23275542, ECO:0000269|PubMed:28602820,
CC       ECO:0000269|PubMed:30373764, ECO:0000269|PubMed:32818467,
CC       ECO:0000269|PubMed:32866000, ECO:0000269|PubMed:34521881,
CC       ECO:0000269|PubMed:7961644, ECO:0000303|PubMed:12213388,
CC       ECO:0000303|PubMed:18076143}.
CC   -!- SUBUNIT: Homodimer (By similarity). Heterodimer; efficient DNA binding
CC       requires dimerization with another bHLH protein (PubMed:10395741,
CC       PubMed:28602820). Interacts with ARNT; the heterodimer ARNT:AHR binds
CC       to core DNA sequence 5'-TGCGTG-3' within the dioxin response element
CC       (DRE) of target gene promoters and activates their transcription
CC       (PubMed:28602820, PubMed:34521881). Binds MYBBP1A (By similarity).
CC       Interacts with coactivators including SRC-1, RIP140 and NOCA7, and with
CC       the corepressor SMRT (PubMed:10395741). Interacts with NEDD8 and
CC       IVNS1ABP (PubMed:12215427, PubMed:16582008). Interacts with BMAL1 (By
CC       similarity). Interacts with HSP90AB1 (By similarity). Interacts with
CC       TIPARP; leading to mono-ADP-ribosylation of AHR and subsequent
CC       inhibition of AHR (PubMed:23275542, PubMed:30373764).
CC       {ECO:0000250|UniProtKB:P30561, ECO:0000269|PubMed:10395741,
CC       ECO:0000269|PubMed:12215427, ECO:0000269|PubMed:16582008,
CC       ECO:0000269|PubMed:23275542, ECO:0000269|PubMed:28602820,
CC       ECO:0000269|PubMed:30373764, ECO:0000269|PubMed:34521881}.
CC   -!- INTERACTION:
CC       P35869; P27540: ARNT; NbExp=6; IntAct=EBI-80780, EBI-80809;
CC       P35869; Q8NI08: NCOA7; NbExp=2; IntAct=EBI-80780, EBI-80799;
CC       P35869; Q9Y618: NCOR2; NbExp=2; IntAct=EBI-80780, EBI-80830;
CC       P35869; P12977: EBNA3; Xeno; NbExp=5; IntAct=EBI-80780, EBI-993115;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:34521881}. Nucleus
CC       {ECO:0000269|PubMed:34521881}. Note=Initially cytoplasmic; upon binding
CC       with ligand and interaction with a HSP90, it translocates to the
CC       nucleus. {ECO:0000269|PubMed:34521881}.
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues tested including blood,
CC       brain, heart, kidney, liver, lung, pancreas and skeletal muscle.
CC       Expressed in retinal photoreceptors (PubMed:29726989).
CC       {ECO:0000269|PubMed:29726989, ECO:0000269|PubMed:7515333,
CC       ECO:0000269|PubMed:8246913}.
CC   -!- INDUCTION: Induced or repressed by TGFB1 and dioxin in a cell-type
CC       specific fashion. Repressed by cAMP, retinoic acid, and 12-O-
CC       tetradecanoyl phorbol-13 acetate (TPA). {ECO:0000269|PubMed:11259615}.
CC   -!- DOMAIN: The PAS 1 domain is essential for dimerization and also
CC       required for AHR:ARNT heterodimerization.
CC       {ECO:0000250|UniProtKB:P30561}.
CC   -!- PTM: Mono-ADP-ribosylated, leading to inhibit transcription activator
CC       activity of AHR. {ECO:0000269|PubMed:30373764}.
CC   -!- DISEASE: Retinitis pigmentosa 85 (RP85) [MIM:618345]: A form of
CC       retinitis pigmentosa, a retinal dystrophy belonging to the group of
CC       pigmentary retinopathies. Retinitis pigmentosa is characterized by
CC       retinal pigment deposits visible on fundus examination and primary loss
CC       of rod photoreceptor cells followed by secondary loss of cone
CC       photoreceptors. Patients typically have night vision blindness and loss
CC       of midperipheral visual field. As their condition progresses, they lose
CC       their far peripheral visual field and eventually central vision as
CC       well. RP85 is an autosomal recessive form manifesting as early-onset
CC       progressive difficulty to adapt in dim light and gradually decreasing
CC       visual acuity in both eyes. {ECO:0000269|PubMed:29726989}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D16354; BAA03857.1; -; mRNA.
DR   EMBL; L19872; AAA16210.1; -; mRNA.
DR   EMBL; AC003075; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236948; EAL24281.1; -; Genomic_DNA.
DR   EMBL; CH471073; EAW93686.1; -; Genomic_DNA.
DR   EMBL; BC069390; AAH69390.1; -; mRNA.
DR   EMBL; BC070080; AAH70080.1; -; mRNA.
DR   EMBL; U28063; AAA92082.1; -; Genomic_DNA.
DR   EMBL; U27656; AAA92082.1; JOINED; Genomic_DNA.
DR   EMBL; U27657; AAA92082.1; JOINED; Genomic_DNA.
DR   EMBL; U28060; AAA92082.1; JOINED; Genomic_DNA.
DR   EMBL; U28061; AAA92082.1; JOINED; Genomic_DNA.
DR   EMBL; U28062; AAA92082.1; JOINED; Genomic_DNA.
DR   EMBL; U28064; AAA92083.1; -; Genomic_DNA.
DR   EMBL; U28066; AAA92084.1; -; Genomic_DNA.
DR   EMBL; U28065; AAA92084.1; JOINED; Genomic_DNA.
DR   EMBL; D38044; BAA07235.1; -; Genomic_DNA.
DR   CCDS; CCDS5366.1; -.
DR   PIR; S59514; S59514.
DR   RefSeq; NP_001612.1; NM_001621.4.
DR   PDB; 5NJ8; X-ray; 3.30 A; A/C=23-273.
DR   PDB; 7ZUB; EM; 2.85 A; D=1-437.
DR   PDBsum; 5NJ8; -.
DR   PDBsum; 7ZUB; -.
DR   AlphaFoldDB; P35869; -.
DR   SMR; P35869; -.
DR   BioGRID; 106699; 183.
DR   CORUM; P35869; -.
DR   DIP; DIP-946N; -.
DR   ELM; P35869; -.
DR   IntAct; P35869; 20.
DR   STRING; 9606.ENSP00000242057; -.
DR   BindingDB; P35869; -.
DR   ChEMBL; CHEMBL3201; -.
DR   DrugBank; DB08624; 1-[(4S)-4-amino-5-(1,3-benzothiazol-2-yl)-5-oxopentyl]guanidine.
DR   DrugBank; DB01076; Atorvastatin.
DR   DrugBank; DB06732; beta-Naphthoflavone.
DR   DrugBank; DB12328; Cantharidin.
DR   DrugBank; DB13009; Carbendazim.
DR   DrugBank; DB08995; Diosmin.
DR   DrugBank; DB07715; Emodin.
DR   DrugBank; DB12116; Epigallocatechin gallate.
DR   DrugBank; DB00499; Flutamide.
DR   DrugBank; DB01404; Ginseng.
DR   DrugBank; DB16862; Indigo.
DR   DrugBank; DB12379; Indirubin.
DR   DrugBank; DB02052; Indirubin-3'-monoxime.
DR   DrugBank; DB11937; Kynurenic Acid.
DR   DrugBank; DB01097; Leflunomide.
DR   DrugBank; DB00379; Mexiletine.
DR   DrugBank; DB00393; Nimodipine.
DR   DrugBank; DB00338; Omeprazole.
DR   DrugBank; DB04216; Quercetin.
DR   DrugBank; DB02709; Resveratrol.
DR   DrugBank; DB06083; Tapinarof.
DR   DrugCentral; P35869; -.
DR   GuidetoPHARMACOLOGY; 2951; -.
DR   iPTMnet; P35869; -.
DR   PhosphoSitePlus; P35869; -.
DR   BioMuta; AHR; -.
DR   DMDM; 3041653; -.
DR   EPD; P35869; -.
DR   jPOST; P35869; -.
DR   MassIVE; P35869; -.
DR   MaxQB; P35869; -.
DR   PaxDb; P35869; -.
DR   PeptideAtlas; P35869; -.
DR   ProteomicsDB; 55159; -.
DR   Antibodypedia; 3909; 1085 antibodies from 46 providers.
DR   DNASU; 196; -.
DR   Ensembl; ENST00000242057.9; ENSP00000242057.4; ENSG00000106546.14.
DR   Ensembl; ENST00000463496.1; ENSP00000436466.1; ENSG00000106546.14.
DR   GeneID; 196; -.
DR   KEGG; hsa:196; -.
DR   MANE-Select; ENST00000242057.9; ENSP00000242057.4; NM_001621.5; NP_001612.1.
DR   UCSC; uc011jxz.2; human.
DR   AGR; HGNC:348; -.
DR   CTD; 196; -.
DR   DisGeNET; 196; -.
DR   GeneCards; AHR; -.
DR   HGNC; HGNC:348; AHR.
DR   HPA; ENSG00000106546; Low tissue specificity.
DR   MalaCards; AHR; -.
DR   MIM; 600253; gene.
DR   MIM; 618345; phenotype.
DR   neXtProt; NX_P35869; -.
DR   OpenTargets; ENSG00000106546; -.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   PharmGKB; PA24641; -.
DR   VEuPathDB; HostDB:ENSG00000106546; -.
DR   eggNOG; KOG3560; Eukaryota.
DR   GeneTree; ENSGT00940000154486; -.
DR   HOGENOM; CLU_010044_1_1_1; -.
DR   InParanoid; P35869; -.
DR   OMA; GCDAKGQ; -.
DR   OrthoDB; 5360131at2759; -.
DR   PhylomeDB; P35869; -.
DR   TreeFam; TF352074; -.
DR   PathwayCommons; P35869; -.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-211945; Phase I - Functionalization of compounds.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   Reactome; R-HSA-211981; Xenobiotics.
DR   Reactome; R-HSA-8937144; Aryl hydrocarbon receptor signalling.
DR   SignaLink; P35869; -.
DR   SIGNOR; P35869; -.
DR   BioGRID-ORCS; 196; 95 hits in 1202 CRISPR screens.
DR   ChiTaRS; AHR; human.
DR   GeneWiki; Aryl_hydrocarbon_receptor; -.
DR   GenomeRNAi; 196; -.
DR   Pharos; P35869; Tclin.
DR   PRO; PR:P35869; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P35869; protein.
DR   Bgee; ENSG00000106546; Expressed in visceral pleura and 194 other tissues.
DR   ExpressionAtlas; P35869; baseline and differential.
DR   Genevisible; P35869; HS.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0034752; C:cytosolic aryl hydrocarbon receptor complex; TAS:DFLAT.
DR   GO; GO:0034753; C:nuclear aryl hydrocarbon receptor complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IMP:CAFA.
DR   GO; GO:0005667; C:transcription regulator complex; TAS:DFLAT.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0003677; F:DNA binding; IDA:DFLAT.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0070888; F:E-box binding; ISS:UniProtKB.
DR   GO; GO:0051879; F:Hsp90 protein binding; IDA:BHF-UCL.
DR   GO; GO:0004879; F:nuclear receptor activity; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0017025; F:TBP-class protein binding; IPI:CAFA.
DR   GO; GO:0001094; F:TFIID-class transcription factor complex binding; IPI:CAFA.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:DFLAT.
DR   GO; GO:0001223; F:transcription coactivator binding; IPI:CAFA.
DR   GO; GO:0140537; F:transcription regulator activator activity; IDA:UniProt.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0001568; P:blood vessel development; NAS:DFLAT.
DR   GO; GO:0019933; P:cAMP-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:1904613; P:cellular response to 2,3,7,8-tetrachlorodibenzodioxine; IDA:UniProtKB.
DR   GO; GO:0071320; P:cellular response to cAMP; IDA:UniProtKB.
DR   GO; GO:1904322; P:cellular response to forskolin; IDA:UniProtKB.
DR   GO; GO:0071219; P:cellular response to molecule of bacterial origin; IDA:UniProt.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IDA:UniProt.
DR   GO; GO:0002841; P:negative regulation of T cell mediated immune response to tumor cell; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0002819; P:regulation of adaptive immune response; IDA:UniProtKB.
DR   GO; GO:0030888; P:regulation of B cell proliferation; IDA:DFLAT.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0010468; P:regulation of gene expression; IDA:DFLAT.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:DFLAT.
DR   GO; GO:0009636; P:response to toxic substance; IDA:UniProtKB.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IDA:UniProtKB.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:DFLAT.
DR   CDD; cd11436; bHLH-PAS_AhR; 1.
DR   CDD; cd00130; PAS; 2.
DR   DisProt; DP00381; -.
DR   Gene3D; 4.10.280.10; Helix-loop-helix DNA-binding domain; 1.
DR   Gene3D; 3.30.450.20; PAS domain; 2.
DR   InterPro; IPR033348; AHR_bHLH.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   InterPro; IPR013655; PAS_fold_3.
DR   PANTHER; PTHR10649; ARYL HYDROCARBON RECEPTOR; 1.
DR   PANTHER; PTHR10649:SF9; ARYL HYDROCARBON RECEPTOR; 1.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   Pfam; PF08447; PAS_3; 1.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; HLH, helix-loop-helix DNA-binding domain; 1.
DR   SUPFAM; SSF55785; PYP-like sensor domain (PAS domain); 2.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; ADP-ribosylation; Biological rhythms;
KW   Cell cycle; Cytoplasm; DNA-binding; Nucleus; Receptor; Reference proteome;
KW   Repeat; Repressor; Retinitis pigmentosa; Transcription;
KW   Transcription regulation.
FT   PROPEP          1..10
FT                   /evidence="ECO:0000250|UniProtKB:P30561"
FT                   /id="PRO_0000013450"
FT   CHAIN           11..848
FT                   /note="Aryl hydrocarbon receptor"
FT                   /id="PRO_0000013451"
FT   DOMAIN          27..80
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   DOMAIN          111..181
FT                   /note="PAS 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          275..342
FT                   /note="PAS 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          348..386
FT                   /note="PAC"
FT   REGION          1..39
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          38..66
FT                   /note="DNA-binding"
FT                   /evidence="ECO:0000269|PubMed:28602820,
FT                   ECO:0000269|PubMed:34521881"
FT   REGION          50..82
FT                   /note="Required for maintaining the overall integrity of
FT                   the AHR:ARNT heterodimer and its transcriptional activity"
FT                   /evidence="ECO:0000269|PubMed:34521881"
FT   REGION          118..126
FT                   /note="Required for maintaining the overall integrity of
FT                   the AHR:ARNT heterodimer and its transcriptional activity"
FT                   /evidence="ECO:0000269|PubMed:34521881"
FT   REGION          266..268
FT                   /note="Required for maintaining the overall integrity of
FT                   the AHR:ARNT heterodimer and its transcriptional activity"
FT                   /evidence="ECO:0000250|UniProtKB:P30561"
FT   REGION          824..848
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           13..16
FT                   /note="Nuclear localization signal 1"
FT                   /evidence="ECO:0000269|PubMed:34521881"
FT   MOTIF           37..42
FT                   /note="Nuclear localization signal 2"
FT                   /evidence="ECO:0000269|PubMed:34521881"
FT   MOTIF           64..72
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000269|PubMed:34521881"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   VARIANT         517
FT                   /note="P -> S (in dbSNP:rs72552768)"
FT                   /evidence="ECO:0000269|PubMed:11689007"
FT                   /id="VAR_015516"
FT   VARIANT         554
FT                   /note="R -> K (in dbSNP:rs2066853)"
FT                   /evidence="ECO:0000269|PubMed:10739168,
FT                   ECO:0000269|PubMed:11698344, ECO:0000269|PubMed:7550366"
FT                   /id="VAR_009281"
FT   VARIANT         570
FT                   /note="V -> I (in dbSNP:rs4986826)"
FT                   /evidence="ECO:0000269|PubMed:10739168,
FT                   ECO:0000269|PubMed:11689007"
FT                   /id="VAR_009282"
FT   VARIANT         786
FT                   /note="M -> V (in dbSNP:rs72552769)"
FT                   /evidence="ECO:0000269|PubMed:11698344"
FT                   /id="VAR_015517"
FT   MUTAGEN         36
FT                   /note="S->G: Strongly reduces transcription factor
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:34521881"
FT   MUTAGEN         39
FT                   /note="H->G: Almost abolishes transcription factor
FT                   activity. No effect on nuclear translocation upon ligand
FT                   binding."
FT                   /evidence="ECO:0000269|PubMed:34521881"
FT   MUTAGEN         40
FT                   /note="R->D: Abolishes transcription factor activity.
FT                   Alters on nuclear translocation upon ligand binding."
FT                   /evidence="ECO:0000269|PubMed:28602820,
FT                   ECO:0000269|PubMed:34521881"
FT   MUTAGEN         50
FT                   /note="L->D: Abolishes transcription factor activity; when
FT                   associated with D-79 and D-82."
FT                   /evidence="ECO:0000269|PubMed:28602820,
FT                   ECO:0000269|PubMed:34521881"
FT   MUTAGEN         74
FT                   /note="V->D: Interfers with transcription factor activity."
FT                   /evidence="ECO:0000269|PubMed:28602820"
FT   MUTAGEN         79
FT                   /note="A->D: Abolishes transcription factor activity; when
FT                   associated with D-50 and D-82."
FT                   /evidence="ECO:0000269|PubMed:28602820,
FT                   ECO:0000269|PubMed:34521881"
FT   MUTAGEN         82
FT                   /note="F->D: Abolishes transcription factor activity; when
FT                   associated with D-50 and D-79."
FT                   /evidence="ECO:0000269|PubMed:28602820,
FT                   ECO:0000269|PubMed:34521881"
FT   MUTAGEN         118..122
FT                   /note="LLQAL->ELQDE: Strongly reduces transcription factor
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:34521881"
FT   MUTAGEN         118
FT                   /note="L->D: Interfers with transcription factor activity."
FT                   /evidence="ECO:0000269|PubMed:28602820"
FT   MUTAGEN         122
FT                   /note="L->D: Interfers with transcription factor activity."
FT                   /evidence="ECO:0000269|PubMed:28602820"
FT   MUTAGEN         136
FT                   /note="F->D: Interfers with transcription factor activity."
FT                   /evidence="ECO:0000269|PubMed:28602820"
FT   MUTAGEN         154
FT                   /note="I->D: Interfers with transcription factor activity."
FT                   /evidence="ECO:0000269|PubMed:28602820"
FT   MUTAGEN         381
FT                   /note="V->A: Increases specific ligand binding."
FT                   /evidence="ECO:0000269|PubMed:7961644"
FT   MUTAGEN         381
FT                   /note="V->D: Abolishes specific ligand binding."
FT                   /evidence="ECO:0000269|PubMed:7961644"
FT   MUTAGEN         381
FT                   /note="V->L,G: No effect on specific ligand binding."
FT                   /evidence="ECO:0000269|PubMed:7961644"
FT   CONFLICT        191
FT                   /note="E -> EG (in Ref. 8; AAA92082)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        340..341
FT                   /note="MI -> SD (in Ref. 9)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        807..848
FT                   /note="LNETYPAELNNINNTQTTTHLQPLHHPSEARPFPDLTSSGFL -> FK (in
FT                   Ref. 1; BAA03857)"
FT                   /evidence="ECO:0000305"
FT   HELIX           35..52
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   STRAND          54..56
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   HELIX           58..61
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   HELIX           66..86
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   HELIX           113..121
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   STRAND          122..124
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   STRAND          126..130
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   STRAND          134..138
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   HELIX           142..146
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   HELIX           150..152
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   TURN            153..155
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   HELIX           158..161
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   HELIX           164..174
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   STRAND          217..224
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   STRAND          235..246
FT                   /evidence="ECO:0007829|PDB:5NJ8"
FT   STRAND          262..270
FT                   /evidence="ECO:0007829|PDB:5NJ8"
SQ   SEQUENCE   848 AA;  96147 MW;  1BFE022871B7B028 CRC64;
     MNSSSANITY ASRKRRKPVQ KTVKPIPAEG IKSNPSKRHR DRLNTELDRL ASLLPFPQDV
     INKLDKLSVL RLSVSYLRAK SFFDVALKSS PTERNGGQDN CRAANFREGL NLQEGEFLLQ
     ALNGFVLVVT TDALVFYASS TIQDYLGFQQ SDVIHQSVYE LIHTEDRAEF QRQLHWALNP
     SQCTESGQGI EEATGLPQTV VCYNPDQIPP ENSPLMERCF ICRLRCLLDN SSGFLAMNFQ
     GKLKYLHGQK KKGKDGSILP PQLALFAIAT PLQPPSILEI RTKNFIFRTK HKLDFTPIGC
     DAKGRIVLGY TEAELCTRGS GYQFIHAADM LYCAESHIRM IKTGESGMIV FRLLTKNNRW
     TWVQSNARLL YKNGRPDYII VTQRPLTDEE GTEHLRKRNT KLPFMFTTGE AVLYEATNPF
     PAIMDPLPLR TKNGTSGKDS ATTSTLSKDS LNPSSLLAAM MQQDESIYLY PASSTSSTAP
     FENNFFNESM NECRNWQDNT APMGNDTILK HEQIDQPQDV NSFAGGHPGL FQDSKNSDLY
     SIMKNLGIDF EDIRHMQNEK FFRNDFSGEV DFRDIDLTDE ILTYVQDSLS KSPFIPSDYQ
     QQQSLALNSS CMVQEHLHLE QQQQHHQKQV VVEPQQQLCQ KMKHMQVNGM FENWNSNQFV
     PFNCPQQDPQ QYNVFTDLHG ISQEFPYKSE MDSMPYTQNF ISCNQPVLPQ HSKCTELDYP
     MGSFEPSPYP TTSSLEDFVT CLQLPENQKH GLNPQSAIIT PQTCYAGAVS MYQCQPEPQH
     THVGQMQYNP VLPGQQAFLN KFQNGVLNET YPAELNNINN TQTTTHLQPL HHPSEARPFP
     DLTSSGFL
//
